The review identified economic evaluations of the following ATMPs: CAR T‐cell therapies tisagenlecleucel (Kymriah) and axicabtagene–ciloleucel (Yescarta), embryonic neural stem cells, tumour infiltrating lymphocytes (TIL), in vitro expanded myoblast (IVM), autologous chondrocyte implantation (ACI), autologous CD34+ cells transduced with a lentiviral vector containing the human adenosine deaminase gene (Strimvelis), and voretigene neparvovec (Luxturna). The gene discussed is CD34; the disease is neoplasm.